AnHorn 安宏生醫

About AnHorn 安宏生醫

AnHorn Medicines is a biopharmaceutical company founded in March 2020 by Dr. Chu-Chiang Lin, headquartered in Taipei, Taiwan. After a career of over two decades in pharmaceutical research and management, including roles at the National Health Research Institutes and TaiGen Biotechnology, Dr. Lin established AnHorn to focus on research-driven drug discovery. The company aims to address the gap in Taiwan's biotech sector, which he noted often prioritizes development over fundamental research.

The company's core business revolves around its proprietary AI-enabled drug discovery platform, AIMCADD® (Artificial intelligence-Bioinformation-Medicinal chemistry-Computer-Aid Drug Design), and its BIGPRO® (Bi-functional liGand induced PROteolysis) technology. This integrated approach is used to develop a new class of drugs that harness the body's natural protein degradation processes to eliminate disease-causing proteins. This strategy targets diseases that are difficult to treat or have developed drug resistance. The primary therapeutic areas of focus are cancer, neurodegenerative diseases, and aging-related conditions. AnHorn's pipeline includes drug candidates for androgenetic alopecia and various cancers such as prostate, pancreatic, and colorectal.

AnHorn's business model involves developing its drug pipeline and forming strategic partnerships with leading global pharmaceutical companies for later-stage development and commercialization. In April 2023, the company successfully completed a $10 million Series A financing round led by Taiwania Capital, with participation from investors such as the Industrial Technology Investment Corporation (ITIC), Black Marble Capital Management, and Sunplus Technology. This funding is intended to accelerate pipeline growth and advance drug candidates, such as AH-001 which has entered Phase I clinical trials in the US for treating androgenetic alopecia.